Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Cancer Medicine|April 18, 2022
Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinibRyota Shibaki, Yuichi Ozawa, Susumu Noguchi, et al.
Cancer Medicine|January 31, 2020
Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array systemMio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, et al.
Scientific Reports|September 14, 2017
Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patientsDaichi Fujimoto, Keiichiro Uehara, Yuki Sato, et al.
BMC Cancer|January 3, 2023
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trialSatoru Miura, Yasuhiro Koh, Koichi Azuma, et al.
BMC Cancer|November 16, 2016
The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinomaYuki Sato, Daichi Fujimoto, Keiichiro Uehara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2017
Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung CancerDaichi Fujimoto, Yuki Sato, Keiichiro Uehara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2022
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, et al.
Molecular Oncology|November 1, 2020
Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L)Kazuko Sakai, Takayuki Takahama, Mototsugu Shimokawa, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancerHibiki Udagawa, Hiroaki Akamatsu, Kentaro Tanaka, et al.
Cancer Immunology, Immunotherapy : CII|January 17, 2022
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitorsYuhei Harutani, Yuichi Ozawa, Eriko Murakami, et al.
Pageof 6